David A Cooper
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Hurst J, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Babiker A, Weber J, Kelleher A, Phillips R, Fisher M, Brown H, Hoffmann M, Pace M, Williams J, Thornhill J, Hamlyn E, Meyerowitz J, Willberg C, Koelsch K, Robinson N, Frater J. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun 2015; 6:8495.
09.10.2015Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
09.10.2015Nat Commun 2015; 6:8495
Hurst Jacob, Kinloch Sabine, Cooper David A, Schechter Mauro, Tambussi Giuseppe, Fidler Sarah, Babiker Abdel, Weber Jonathan, Kelleher Anthony D, Phillips Rodney E, Fisher Martin, Brown Helen, Hoffmann Matthias, Pace Matthew, Williams James P, Thornhill John, Hamlyn Elizabeth, Meyerowitz Jodi, Willberg Chris, Koelsch Kersten K, Robinson Nicola, Frater John
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial
Vernazza P, Craig C, Mori J, Goodrich J, Valdez H, Lazzarin A, Kaplan R, Cooper D, Pulik P, Weil E, Pozniak A, Wang C, Tawadrous M. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr 2013; 62:171-9.
01.02.2013Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial
01.02.2013J Acquir Immune Defic Syndr 2013; 62:171-9
Vernazza Pietro, Craig Charles, Mori Julie, Goodrich James, Valdez Hernan, Lazzarin Adriano, Kaplan Richard, Cooper David A, Pulik Piotr, Weil Elizabeth, Pozniak Anton, Wang Cunshan, Tawadrous Margaret
Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary Analysis Results from an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial
Vernazza P, Craig C, Mori J, Goodrich J, Valdez H, Lazzarin A, Kaplan R, Cooper D, Pulik P, Weil E, Pozniak A, Wang C, Tawadrous M. Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary Analysis Results from an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial. J Acquir Immune Defic Syndr 2012
31.10.2012Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients: Week 48 Primary Analysis Results from an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial
31.10.2012J Acquir Immune Defic Syndr 2012
Vernazza Pietro, Craig Charles, Mori Julie, Goodrich James, Valdez Hernan, Lazzarin Adriano, Kaplan Richard, Cooper David A, Pulik Piotr, Weil Elizabeth, Pozniak Anton, Wang Cunshan, Tawadrous Margaret